Aktieanalys

Moberg Pharma Q4’23: Results in line – focus on Swedish launch - Redeye

Redeye Publicerad: 13 Feb 09:25

Redeye saw a report that came in as expected regarding the results. There were, as expected, no sales in the quarter, and costs were in line with our expectations. The main event in the quarter was the preparation of the official launch of Terclara in Sweden in February and the completion of the enrollment in the North American Phase 3 study.

Länk till analysen i sin helhet: https://www.redeye.se/research/978385/moberg-pharma-q423-results-in-line-focus-on-swedish-launch?utm_source=finwire&utm_medium=RSS

Nyheter om Moberg Pharma

Läses av andra just nu

Innehåller annonslänkar. Investeringar innebär risk (se här)

Tips: 50% rabatt hos fondroboten Opti

Dags att komma igång med sparande? Fondroboten Opti erbjuder en populär spartjänst som är perfekt för regelbundet månadssparande. Just nu får nya kunder som använder Börskollens unika kampanjkod BORSKOLLEN50 automatiskt 50 % rabatt på Optis avgift i 3 månader!